#SOHO 2023 Leukemia

Nitin Jain, MDMeeting News | October 4, 2023
Nitin Jain, MD, joins Chadi Nabhan, MD, MBA, FACP, Host of The HemOnc Pulse, to discuss unmet needs in CLL.
View More
Rami Komrokji, MDAcute Myeloid Leukemia | September 12, 2023
The crew talk about AML and MDS in this episode of The HemOnc Pulse.
Chadi Nabhan, MD, MBA, FACPAcute Myeloid Leukemia | September 12, 2023
Dr. Erba answers this question and more in this interview with Dr. Chadi Nabhan.
Advertisement
Chadi Nabhan, MD, MBA, FACPMeeting News | September 13, 2023
Dr. Nath spoke transplant in patients with AML who are elderly and emphasized the need to include them in clinical trials.
Jorge Cortes, MDVideo Insights | September 14, 2023
Dr. Cortes speaks about the plenary session he delivered during the Eleventh Annual Meeting of SOHO.
Karun Neupane, MDVideo Insights | September 10, 2023
The single-center study was conducted to address gaps in knowledge surrounding minority-predominant populations of patients.
Advertisement
Leah SherwoodAcute Myeloid Leukemia | February 8, 2024
Enrolled patients must be aged 75 years or older or aged 18-74 years with specific comorbidities.
Leah SherwoodMeeting News | September 8, 2023
The trial will enroll approximately 346 patients with treatment-naive TP53-mutated disease or biallelic 17p deletions.
Marina Konopleva, MD, PhDMeeting News | September 8, 2023
Dr. Konopleva explains the controversy and what she sees on the horizon for MRD in AML.
Elias Jabbour, MDAcute Lymphoblastic Leukemia | February 8, 2024
Dr. Jabbour presented data from the study at the Eleventh Annual Meeting of SOHO.
Cecilia BrownChronic Lymphocytic Leukemia | February 8, 2024
Dr. Brown shares what CLL news and session she's watching at the Eleventh Annual Meeting of SOHO.
Cecilia BrownAcute Lymphoblastic Leukemia | September 8, 2023
The award is the society’s “most prestigious award" and “serves to honor those that have been pioneers in their work."
Leah LawrenceAcute Lymphoblastic Leukemia | September 6, 2023
This single-center retrospective study looked at outcomes from 18 patients with AML treated with venetoclax plus an HMA.
Leah LawrenceMeeting News | September 6, 2023
The study included 59 patients with T-ALL with a median age of 20 at diagnosis.
Advertisement
Advertisement
Editorial Board